David Headley, MD
Family Medicine · Port Gibson, MSNPI 1528032406
Payments from drug & device makers
Across 296 payments — averaging $2098.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$371K
- Novartis$159K
- Alnylam Pharmaceuticals Inc.$22K
- Chiesi USA, Inc.$22K
- Novo Nordisk AS$14K
- Amgen$14K
- plus $19K from 19 others
Across 11 payments — averaging $1973.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$9K
- Amgen$7K
- Novartis$6K
- AbbVie$887
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 130 | $371,340 |
| Novartis | 9 | $159,201 |
| Alnylam Pharmaceuticals Inc. | 3 | $22,000 |
| Chiesi USA, Inc. | 7 | $21,861 |
| Novo Nordisk AS | 1 | $14,154 |
| Amgen | 7 | $13,598 |
| AstraZeneca | 6 | $12,745 |
| Astrazeneca UK Limited | 2 | $5,107 |
| GSK | 98 | $531 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| GRT US Holding, Inc. | 4 | $80 |
| Merck | 5 | $66 |
| Novo Nordisk | 3 | $40 |
| SK Life Science, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $32 |
| Abbott | 2 | $31 |
| Vivus LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bioventus LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
How this compares
$621,070 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Port Gibson
- Demetri MarshallPort Gibson$3M
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.